Sutro Biopharma (STRO) — Cash Flow-to-Debt Ratio
Sutro Biopharma (STRO) has a Cash Flow-to-Debt Ratio of -0.13x as of June 2026, meaning its operating cash flow of $-38.29 Million could theoretically repay 0% of its total liabilities ($297.78 Million) in one year. See STRO financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sutro Biopharma Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Sutro Biopharma across 10 annual periods. For the full cash flow conversion analysis, see Sutro Biopharma cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Sutro Biopharma (2016–2025)
Year-by-year debt coverage analysis for Sutro Biopharma. Check Sutro Biopharma cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.58x | $-177.23 Million | $306.28 Million | ▼ -3.5% |
| 2024 | -0.56x | $-191.54 Million | $342.61 Million | ▼ -60.8% |
| 2023 | -0.35x | $-111.62 Million | $321.09 Million | ▼ -1960.0% |
| 2022 | 0.02x | $3.55 Million | $189.90 Million | ▲ +102.0% |
| 2021 | -0.92x | $-81.68 Million | $88.84 Million | ▲ +15.8% |
| 2020 | -1.09x | $-67.80 Million | $62.06 Million | ▲ +1.6% |
| 2019 | -1.11x | $-65.02 Million | $58.58 Million | ▼ -901.6% |
| 2018 | 0.14x | $12.68 Million | $91.60 Million | ▲ +155.9% |
| 2017 | -0.25x | $-37.07 Million | $149.77 Million | ▼ -201.5% |
| 2016 | -0.08x | $-13.15 Million | $160.18 Million | — |